Solid Biosciences
SLDB
114 hedge funds and large institutions have $400M invested in Solid Biosciences in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 14 reducing their positions, and 35 closing their positions.
666% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $155K
286% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 14
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
37% more capital invested
Capital invested by funds: $292M → $400M (+$109M)
4.3% more ownership
Funds ownership: 101.75% → 106.06% (+4.3%)
8% less funds holding
Funds holding: 124 → 114 (-10)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.79M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.24M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.03M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.76M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$21.6M |
| 2 |
VA
VR Adviser
New York
|
-$9.18M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
-$4.59M |
| 4 |
CC
Casdin Capital
New York
|
-$2.87M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.75M |
SLDB Hedge Fund Activity: Q2 2025 in Review
114 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2025, worth a combined $400M — up 37% from $292M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of SLDB and 25 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 54 added.
The largest buyer was BlackRock, adding an estimated $9.79M. The largest seller was Commodore Capital, exiting entirely with an estimated $21.6M sold.
- 114 institutional investors held Solid Biosciences (SLDB) as of Q2 2025, down from 124 in Q1 2025.
- Funds reported $400M of Solid Biosciences stock for Q2 2025, up 37% quarter-over-quarter.
- 25 funds opened new Solid Biosciences positions in Q2 2025 and 35 closed out, a net change of -10 holders.
- The largest Solid Biosciences buyer in Q2 2025 was BlackRock, an estimated $9.79M added.
- The largest Solid Biosciences seller in Q2 2025 was Commodore Capital, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2025.